Gilead Sciences holding off on six trials for its cancer drug Zydelig due to concerns of adverse effects and deaths
The FDA issued an alert about the drug on Monday, and in the warning it warned healthcare professionals that the drug is not approved for previously untreated chronic lymphocytic leukemia.